APA (7th ed.) Citation

Secord, A. A., Lewin, S., Murphy, C., & Method, M. (2022). PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (300). Gynecologic Oncology, 166, S157. https://doi.org/10.1016/S0090-8258(22)01521-9

Chicago Style (17th ed.) Citation

Secord, Angeles Alvarez, Sharyn Lewin, Conleth Murphy, and Michael Method. "PICCOLO: An Open-label, Single Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum Sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate-alpha (FRα) Expression (300)." Gynecologic Oncology 166 (2022): S157. https://doi.org/10.1016/S0090-8258(22)01521-9.

MLA (9th ed.) Citation

Secord, Angeles Alvarez, et al. "PICCOLO: An Open-label, Single Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum Sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate-alpha (FRα) Expression (300)." Gynecologic Oncology, vol. 166, 2022, p. S157, https://doi.org/10.1016/S0090-8258(22)01521-9.